Silence Therapeutics (SLN) Financials: Revenue & Earnings
SLN$19.73+0.03 +0.13%
$932.16M
Market Cap
-5.19
P/E
—
Forward P/E
28
Score
Silence Therapeutics (SLN) Financials: Revenue & Earnings
SLN price $19.73 +0.03 +0.13%
- Ticker
- SLN
- Price
- $19.73
- Change
- +0.03 +0.13%
- Market cap ?
- $932.16M
- P/E ?
- -5.19
- Dividend yield ?
- 0.00%
- Beta ?
- 1.42
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 28
- Value
- 38
- Quality
- 33
- Growth
- 12
Stocklytics score rationale: value 38, quality 33, growth 12.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 770000 | 16000 | 0 | 244000 | 5479000 | 12415000 | 17653047 | 25375000 | 43258000 | 559000 |
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of…
Earnings and financials
Silence Therapeutics plc (SLN) trades at $19.73, with a market cap of $932.16M and a trailing P/E of -5.19. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 770000 | 16000 | 0 | 244000 | 5479000 | 12415000 | 17653047 | 25375000 | 43258000 | 559000 |
Insights · Dividends · Forecast · Financials · Learn